Loading…
Applicability of the MASK-Air® App to Severe Asthma Treated with Biologic Molecules: A Pilot Study
MASK-air®, a good practice of the DG Santé, has been fully validated in allergic rhinitis, but little is known about its applicability to asthmatics. We explored whether the MASK-air® application is applicable to patients with severe asthma. Severe asthmatics were proposed to use the MASK-air® appli...
Saved in:
Published in: | International journal of molecular sciences 2022-10, Vol.23 (19), p.11470 |
---|---|
Main Authors: | , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c458t-dc86295452447bad027262dd0b0015ca5db2fe9f5ab0c9f945c1ab0542a9ffcb3 |
---|---|
cites | cdi_FETCH-LOGICAL-c458t-dc86295452447bad027262dd0b0015ca5db2fe9f5ab0c9f945c1ab0542a9ffcb3 |
container_end_page | |
container_issue | 19 |
container_start_page | 11470 |
container_title | International journal of molecular sciences |
container_volume | 23 |
creator | Benfante, Alida Sousa-Pinto, Bernardo Pillitteri, Gianluca Battaglia, Salvatore Fonseca, Joao Bousquet, Jean Scichilone, Nicola |
description | MASK-air®, a good practice of the DG Santé, has been fully validated in allergic rhinitis, but little is known about its applicability to asthmatics. We explored whether the MASK-air® application is applicable to patients with severe asthma. Severe asthmatics were proposed to use the MASK-air® application for 6 months, along with best practice treatment. Treatment of the patients was not changed based on the application results. The evolution of the visual analogue scales (VAS) for asthma, shortness of breath, rhinitis, conjunctivitis, work, and sleep was monitored using MASK-air®. Adherence to MASK-air® and to the asthma treatment was also checked. Thirteen patients reported on 1229 days of MASK-air® use. The average application adherence was 51.8% (range: 19.7–98.9%). There was no correlation between application and medication adherence. Highly variably trends were found for the VAS for asthma. Five patients had over 90% well-controlled days, four had well- or moderately controlled asthma (with up to 20% uncontrolled days), one patient had moderately controlled asthma with approximately 20% uncontrolled days, and one patient had 80% uncontrolled days. Highly significant correlations were found for the VAS for asthma, and other patients reported VASs for work, dyspnea, sleep, and rhinitis. MASK-air® can be used in patients with severe asthma. VAS asthma appears to be an interesting patient-reported outcome highly correlated with dyspnea and impacts on work. Adherence to the application was better than that for rhinitis, but it needs to be improved. |
doi_str_mv | 10.3390/ijms231911470 |
format | article |
fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_d42c52ef40e749faa2167cd98807a539</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_d42c52ef40e749faa2167cd98807a539</doaj_id><sourcerecordid>2725199398</sourcerecordid><originalsourceid>FETCH-LOGICAL-c458t-dc86295452447bad027262dd0b0015ca5db2fe9f5ab0c9f945c1ab0542a9ffcb3</originalsourceid><addsrcrecordid>eNpdkk1v1DAQhiNERUvhyN0SFy4BfyYxB6RQ8VG1FUhbzpZjj3e9ctaL7RTtn-JH8MvIshXq9uRXnkePZkZTVa8IfsuYxO_8esyUEUkIb_GT6oxwSmuMm_bpg3xaPc95jTFlVMhn1Slr5tS25Kwy_XYbvNGDD77sUHSorADd9Iuruvfpz28011GJaAF3kAD1uaxGjW4T6AIW_fJlhT76GOLSG3QTA5gpQH6PevTdh1jQokx296I6cTpkeHn_nlc_Pn-6vfhaX3_7cnnRX9eGi67U1nQNlYILynk7aItpSxtqLR4wJsJoYQfqQDqhB2ykk1wYMkfBqZbOmYGdV5cHr416rbbJjzrtVNRe_fuIaal0Kt4EUJZTIyg4jqHl0mlNSdMaK7sOt1owObs-HFzbaRjBGtiUpMOR9Liy8Su1jHdKikbyBs-CN_eCFH9OkIsafTYQgt5AnLKahxNESia7GX39CF3HKW3mVe0pTjvBuj1VHyiTYs4J3P9mCFb7U1BHp8D-Amt8pZk</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2724285388</pqid></control><display><type>article</type><title>Applicability of the MASK-Air® App to Severe Asthma Treated with Biologic Molecules: A Pilot Study</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Benfante, Alida ; Sousa-Pinto, Bernardo ; Pillitteri, Gianluca ; Battaglia, Salvatore ; Fonseca, Joao ; Bousquet, Jean ; Scichilone, Nicola</creator><creatorcontrib>Benfante, Alida ; Sousa-Pinto, Bernardo ; Pillitteri, Gianluca ; Battaglia, Salvatore ; Fonseca, Joao ; Bousquet, Jean ; Scichilone, Nicola</creatorcontrib><description>MASK-air®, a good practice of the DG Santé, has been fully validated in allergic rhinitis, but little is known about its applicability to asthmatics. We explored whether the MASK-air® application is applicable to patients with severe asthma. Severe asthmatics were proposed to use the MASK-air® application for 6 months, along with best practice treatment. Treatment of the patients was not changed based on the application results. The evolution of the visual analogue scales (VAS) for asthma, shortness of breath, rhinitis, conjunctivitis, work, and sleep was monitored using MASK-air®. Adherence to MASK-air® and to the asthma treatment was also checked. Thirteen patients reported on 1229 days of MASK-air® use. The average application adherence was 51.8% (range: 19.7–98.9%). There was no correlation between application and medication adherence. Highly variably trends were found for the VAS for asthma. Five patients had over 90% well-controlled days, four had well- or moderately controlled asthma (with up to 20% uncontrolled days), one patient had moderately controlled asthma with approximately 20% uncontrolled days, and one patient had 80% uncontrolled days. Highly significant correlations were found for the VAS for asthma, and other patients reported VASs for work, dyspnea, sleep, and rhinitis. MASK-air® can be used in patients with severe asthma. VAS asthma appears to be an interesting patient-reported outcome highly correlated with dyspnea and impacts on work. Adherence to the application was better than that for rhinitis, but it needs to be improved.</description><identifier>ISSN: 1422-0067</identifier><identifier>ISSN: 1661-6596</identifier><identifier>EISSN: 1422-0067</identifier><identifier>DOI: 10.3390/ijms231911470</identifier><identifier>PMID: 36232771</identifier><language>eng</language><publisher>Basel: MDPI AG</publisher><subject>Air monitoring ; Allergic rhinitis ; application ; Asthma ; Best practice ; biologic molecules ; Clinical outcomes ; Collaboration ; Conjunctivitis ; Correlation ; Disease control ; Dyspnea ; Hay fever ; Integrated delivery systems ; Patient compliance ; Patients ; Physicians ; Respiration ; Rhinitis ; severe asthma ; Telemedicine ; Trends ; visual analogue scales</subject><ispartof>International journal of molecular sciences, 2022-10, Vol.23 (19), p.11470</ispartof><rights>2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2022 by the authors. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c458t-dc86295452447bad027262dd0b0015ca5db2fe9f5ab0c9f945c1ab0542a9ffcb3</citedby><cites>FETCH-LOGICAL-c458t-dc86295452447bad027262dd0b0015ca5db2fe9f5ab0c9f945c1ab0542a9ffcb3</cites><orcidid>0000-0002-0887-8796 ; 0000-0001-6400-6573 ; 0000-0002-2867-917X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2724285388/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2724285388?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25751,27922,27923,37010,37011,44588,53789,53791,74896</link.rule.ids></links><search><creatorcontrib>Benfante, Alida</creatorcontrib><creatorcontrib>Sousa-Pinto, Bernardo</creatorcontrib><creatorcontrib>Pillitteri, Gianluca</creatorcontrib><creatorcontrib>Battaglia, Salvatore</creatorcontrib><creatorcontrib>Fonseca, Joao</creatorcontrib><creatorcontrib>Bousquet, Jean</creatorcontrib><creatorcontrib>Scichilone, Nicola</creatorcontrib><title>Applicability of the MASK-Air® App to Severe Asthma Treated with Biologic Molecules: A Pilot Study</title><title>International journal of molecular sciences</title><description>MASK-air®, a good practice of the DG Santé, has been fully validated in allergic rhinitis, but little is known about its applicability to asthmatics. We explored whether the MASK-air® application is applicable to patients with severe asthma. Severe asthmatics were proposed to use the MASK-air® application for 6 months, along with best practice treatment. Treatment of the patients was not changed based on the application results. The evolution of the visual analogue scales (VAS) for asthma, shortness of breath, rhinitis, conjunctivitis, work, and sleep was monitored using MASK-air®. Adherence to MASK-air® and to the asthma treatment was also checked. Thirteen patients reported on 1229 days of MASK-air® use. The average application adherence was 51.8% (range: 19.7–98.9%). There was no correlation between application and medication adherence. Highly variably trends were found for the VAS for asthma. Five patients had over 90% well-controlled days, four had well- or moderately controlled asthma (with up to 20% uncontrolled days), one patient had moderately controlled asthma with approximately 20% uncontrolled days, and one patient had 80% uncontrolled days. Highly significant correlations were found for the VAS for asthma, and other patients reported VASs for work, dyspnea, sleep, and rhinitis. MASK-air® can be used in patients with severe asthma. VAS asthma appears to be an interesting patient-reported outcome highly correlated with dyspnea and impacts on work. Adherence to the application was better than that for rhinitis, but it needs to be improved.</description><subject>Air monitoring</subject><subject>Allergic rhinitis</subject><subject>application</subject><subject>Asthma</subject><subject>Best practice</subject><subject>biologic molecules</subject><subject>Clinical outcomes</subject><subject>Collaboration</subject><subject>Conjunctivitis</subject><subject>Correlation</subject><subject>Disease control</subject><subject>Dyspnea</subject><subject>Hay fever</subject><subject>Integrated delivery systems</subject><subject>Patient compliance</subject><subject>Patients</subject><subject>Physicians</subject><subject>Respiration</subject><subject>Rhinitis</subject><subject>severe asthma</subject><subject>Telemedicine</subject><subject>Trends</subject><subject>visual analogue scales</subject><issn>1422-0067</issn><issn>1661-6596</issn><issn>1422-0067</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpdkk1v1DAQhiNERUvhyN0SFy4BfyYxB6RQ8VG1FUhbzpZjj3e9ctaL7RTtn-JH8MvIshXq9uRXnkePZkZTVa8IfsuYxO_8esyUEUkIb_GT6oxwSmuMm_bpg3xaPc95jTFlVMhn1Slr5tS25Kwy_XYbvNGDD77sUHSorADd9Iuruvfpz28011GJaAF3kAD1uaxGjW4T6AIW_fJlhT76GOLSG3QTA5gpQH6PevTdh1jQokx296I6cTpkeHn_nlc_Pn-6vfhaX3_7cnnRX9eGi67U1nQNlYILynk7aItpSxtqLR4wJsJoYQfqQDqhB2ykk1wYMkfBqZbOmYGdV5cHr416rbbJjzrtVNRe_fuIaal0Kt4EUJZTIyg4jqHl0mlNSdMaK7sOt1owObs-HFzbaRjBGtiUpMOR9Liy8Su1jHdKikbyBs-CN_eCFH9OkIsafTYQgt5AnLKahxNESia7GX39CF3HKW3mVe0pTjvBuj1VHyiTYs4J3P9mCFb7U1BHp8D-Amt8pZk</recordid><startdate>20221001</startdate><enddate>20221001</enddate><creator>Benfante, Alida</creator><creator>Sousa-Pinto, Bernardo</creator><creator>Pillitteri, Gianluca</creator><creator>Battaglia, Salvatore</creator><creator>Fonseca, Joao</creator><creator>Bousquet, Jean</creator><creator>Scichilone, Nicola</creator><general>MDPI AG</general><general>MDPI</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-0887-8796</orcidid><orcidid>https://orcid.org/0000-0001-6400-6573</orcidid><orcidid>https://orcid.org/0000-0002-2867-917X</orcidid></search><sort><creationdate>20221001</creationdate><title>Applicability of the MASK-Air® App to Severe Asthma Treated with Biologic Molecules: A Pilot Study</title><author>Benfante, Alida ; Sousa-Pinto, Bernardo ; Pillitteri, Gianluca ; Battaglia, Salvatore ; Fonseca, Joao ; Bousquet, Jean ; Scichilone, Nicola</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c458t-dc86295452447bad027262dd0b0015ca5db2fe9f5ab0c9f945c1ab0542a9ffcb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Air monitoring</topic><topic>Allergic rhinitis</topic><topic>application</topic><topic>Asthma</topic><topic>Best practice</topic><topic>biologic molecules</topic><topic>Clinical outcomes</topic><topic>Collaboration</topic><topic>Conjunctivitis</topic><topic>Correlation</topic><topic>Disease control</topic><topic>Dyspnea</topic><topic>Hay fever</topic><topic>Integrated delivery systems</topic><topic>Patient compliance</topic><topic>Patients</topic><topic>Physicians</topic><topic>Respiration</topic><topic>Rhinitis</topic><topic>severe asthma</topic><topic>Telemedicine</topic><topic>Trends</topic><topic>visual analogue scales</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Benfante, Alida</creatorcontrib><creatorcontrib>Sousa-Pinto, Bernardo</creatorcontrib><creatorcontrib>Pillitteri, Gianluca</creatorcontrib><creatorcontrib>Battaglia, Salvatore</creatorcontrib><creatorcontrib>Fonseca, Joao</creatorcontrib><creatorcontrib>Bousquet, Jean</creatorcontrib><creatorcontrib>Scichilone, Nicola</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>International journal of molecular sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Benfante, Alida</au><au>Sousa-Pinto, Bernardo</au><au>Pillitteri, Gianluca</au><au>Battaglia, Salvatore</au><au>Fonseca, Joao</au><au>Bousquet, Jean</au><au>Scichilone, Nicola</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Applicability of the MASK-Air® App to Severe Asthma Treated with Biologic Molecules: A Pilot Study</atitle><jtitle>International journal of molecular sciences</jtitle><date>2022-10-01</date><risdate>2022</risdate><volume>23</volume><issue>19</issue><spage>11470</spage><pages>11470-</pages><issn>1422-0067</issn><issn>1661-6596</issn><eissn>1422-0067</eissn><abstract>MASK-air®, a good practice of the DG Santé, has been fully validated in allergic rhinitis, but little is known about its applicability to asthmatics. We explored whether the MASK-air® application is applicable to patients with severe asthma. Severe asthmatics were proposed to use the MASK-air® application for 6 months, along with best practice treatment. Treatment of the patients was not changed based on the application results. The evolution of the visual analogue scales (VAS) for asthma, shortness of breath, rhinitis, conjunctivitis, work, and sleep was monitored using MASK-air®. Adherence to MASK-air® and to the asthma treatment was also checked. Thirteen patients reported on 1229 days of MASK-air® use. The average application adherence was 51.8% (range: 19.7–98.9%). There was no correlation between application and medication adherence. Highly variably trends were found for the VAS for asthma. Five patients had over 90% well-controlled days, four had well- or moderately controlled asthma (with up to 20% uncontrolled days), one patient had moderately controlled asthma with approximately 20% uncontrolled days, and one patient had 80% uncontrolled days. Highly significant correlations were found for the VAS for asthma, and other patients reported VASs for work, dyspnea, sleep, and rhinitis. MASK-air® can be used in patients with severe asthma. VAS asthma appears to be an interesting patient-reported outcome highly correlated with dyspnea and impacts on work. Adherence to the application was better than that for rhinitis, but it needs to be improved.</abstract><cop>Basel</cop><pub>MDPI AG</pub><pmid>36232771</pmid><doi>10.3390/ijms231911470</doi><orcidid>https://orcid.org/0000-0002-0887-8796</orcidid><orcidid>https://orcid.org/0000-0001-6400-6573</orcidid><orcidid>https://orcid.org/0000-0002-2867-917X</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1422-0067 |
ispartof | International journal of molecular sciences, 2022-10, Vol.23 (19), p.11470 |
issn | 1422-0067 1661-6596 1422-0067 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_d42c52ef40e749faa2167cd98807a539 |
source | Publicly Available Content Database; PubMed Central |
subjects | Air monitoring Allergic rhinitis application Asthma Best practice biologic molecules Clinical outcomes Collaboration Conjunctivitis Correlation Disease control Dyspnea Hay fever Integrated delivery systems Patient compliance Patients Physicians Respiration Rhinitis severe asthma Telemedicine Trends visual analogue scales |
title | Applicability of the MASK-Air® App to Severe Asthma Treated with Biologic Molecules: A Pilot Study |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T19%3A45%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Applicability%20of%20the%20MASK-Air%C2%AE%20App%20to%20Severe%20Asthma%20Treated%20with%20Biologic%20Molecules:%20A%20Pilot%20Study&rft.jtitle=International%20journal%20of%20molecular%20sciences&rft.au=Benfante,%20Alida&rft.date=2022-10-01&rft.volume=23&rft.issue=19&rft.spage=11470&rft.pages=11470-&rft.issn=1422-0067&rft.eissn=1422-0067&rft_id=info:doi/10.3390/ijms231911470&rft_dat=%3Cproquest_doaj_%3E2725199398%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c458t-dc86295452447bad027262dd0b0015ca5db2fe9f5ab0c9f945c1ab0542a9ffcb3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2724285388&rft_id=info:pmid/36232771&rfr_iscdi=true |